153 related articles for article (PubMed ID: 34486071)
1. Two experts and a newbie: [
Stotz S; Kinzler J; Nies AT; Schwab M; Maurer A
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):834-846. PubMed ID: 34486071
[TBL] [Abstract][Full Text] [Related]
2. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of [
Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
Mol Pharm; 2024 May; 21(5):2606-2621. PubMed ID: 38606716
[TBL] [Abstract][Full Text] [Related]
4. In vivo visualization of PARP inhibitor pharmacodynamics.
McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
[TBL] [Abstract][Full Text] [Related]
5. [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
Pantel AR; Gitto SB; Makvandi M; Kim H; Medvedv S; Weeks JK; Torigian DA; Hsieh CJ; Ferman B; Latif NA; Tanyi JL; Martin LP; Lanzo SM; Liu F; Cao Q; Mills GB; Doot RK; Mankoff DA; Mach RH; Lin LL; Simpkins F
Clin Cancer Res; 2023 Apr; 29(8):1515-1527. PubMed ID: 36441795
[TBL] [Abstract][Full Text] [Related]
6. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Michel LS; Dyroff S; Brooks FJ; Spayd KJ; Lim S; Engle JT; Phillips S; Tan B; Wang-Gillam A; Bognar C; Chu W; Zhou D; Mach RH; Laforest R; Chen DL
Radiology; 2017 Feb; 282(2):453-463. PubMed ID: 27841728
[TBL] [Abstract][Full Text] [Related]
7. The Development of
Lee HS; Schwarz SW; Schubert EK; Chen DL; Doot RK; Makvandi M; Lin LL; McDonald ES; Mankoff DA; Mach RH
Radiol Imaging Cancer; 2022 Jan; 4(1):e210070. PubMed ID: 35089089
[TBL] [Abstract][Full Text] [Related]
8. Solid phase radiosynthesis of an olaparib derivative using 4-[
Xu J; Chen H; Rogers BE; Katzenellenbogen JA; Zhou D
Nucl Med Biol; 2022; 114-115():65-70. PubMed ID: 36193598
[TBL] [Abstract][Full Text] [Related]
9. Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
Dehdashti F; Reimers MA; Shoghi KI; Chen DL; Luo J; Rogers B; Pachynski RK; Sreekumar S; Weimholt C; Zhou D
Mol Imaging Biol; 2022 Dec; 24(6):853-861. PubMed ID: 35701722
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging of PARP in cancer: state-of-the-art.
Filippi L; Urso L; Frantellizzi V; Marzo K; Marzola MC; Schillaci O; Evangelista L
Expert Rev Mol Diagn; 2023; 23(12):1167-1174. PubMed ID: 38009232
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.
Zhou D; Chu W; Xu J; Jones LA; Peng X; Li S; Chen DL; Mach RH
Bioorg Med Chem; 2014 Mar; 22(5):1700-7. PubMed ID: 24503274
[TBL] [Abstract][Full Text] [Related]
13. Safety and Feasibility of PARP1/2 Imaging with
Schöder H; França PDS; Nakajima R; Burnazi E; Roberts S; Brand C; Grkovski M; Mauguen A; Dunphy MP; Ghossein RA; Lyashchenko SK; Lewis JS; O'Donoghue JA; Ganly I; Patel SG; Lee NY; Reiner T
Clin Cancer Res; 2020 Jul; 26(13):3110-3116. PubMed ID: 32245901
[TBL] [Abstract][Full Text] [Related]
14. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
15. Discriminating radiation injury from recurrent tumor with [
Donabedian PL; Kossatz S; Engelbach JA; Jannetti SA; Carney B; Young RJ; Weber WA; Garbow JR; Reiner T
EJNMMI Res; 2018 Jul; 8(1):59. PubMed ID: 29974335
[TBL] [Abstract][Full Text] [Related]
16. Impact of structural alterations on the radiopharmacological profile of
Tietz O; Marshall A; Bergman C; Wuest M; Wuest F
Nucl Med Biol; 2018; 62-63():9-17. PubMed ID: 29800798
[TBL] [Abstract][Full Text] [Related]
17. High-Contrast CXCR4-Targeted
Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
Carney B; Carlucci G; Salinas B; Di Gialleonardo V; Kossatz S; Vansteene A; Longo VA; Bolaender A; Chiosis G; Keshari KR; Weber WA; Reiner T
Mol Imaging Biol; 2016 Jun; 18(3):386-92. PubMed ID: 26493053
[TBL] [Abstract][Full Text] [Related]
19. Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21.
Kim DS; Camacho CV; Nagari A; Malladi VS; Challa S; Kraus WL
Mol Cell; 2019 Sep; 75(6):1270-1285.e14. PubMed ID: 31351877
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely.
Patel PR; Senyuk V; Sweiss K; Calip GS; Pan D; Rodriguez N; Oh A; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1273-1279. PubMed ID: 32194286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
